<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>BioRestorative Announces Positive Outcome from Type B Meeting with FDA</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>BioRestorative Announces Positive Outcome from Type B Meeting with FDA</h1>

    <table>
      <tr><th>Ticker</th><td>BRTX</td></tr>
      <tr><th>Float</th><td>6.9 M</td></tr>
      <tr><th>IO</th><td>9.20%</td></tr>
      <tr><th>MC</th><td>5.7 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>BioRestorative (NASDAQ: BRTX) reported a positive Type B meeting with the FDA regarding a potential expedited Biologics License Application (BLA) pathway for its Fast-Track-designated BRTX-100 program to treat chronic lumbar disc disease (cLDD). The FDA raised no clinical safety concerns from the ongoing 99-patient Phase 2 trial, endorsed the Company’s proposed Phase 3 design (outcome assessments, dosing, eligibility), sample size and powering assumptions subject to final IND review, and confirmed alignment on CMC activities. BioRestorative has initiated Phase 3 enabling work and intends to submit a Phase 3 IND in the second half of 2026. The release reiterates Fast Track benefits and notes that forward-looking statements are subject to customary risks.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>FDA raised no clinical safety concerns from the ongoing Phase 2 BRTX-100 trial</li><li>FDA endorsed proposed Phase 3 study design, dosing, eligibility, sample size and powering assumptions (pending final IND review)</li><li>FDA confirmed alignment on CMC activities prior to IND submission</li><li>Company initiated Phase 3 enabling activities and aims to submit Phase 3 IND in H2 2026</li><li>BRTX-100 holds FDA Fast Track designation (granted Feb 2025), which can enable expedited review and potential accelerated BLA</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Accelerated BLA pathway remains potential, not guaranteed</li><li>Phase 3 IND has not yet been submitted (targeted for second half of 2026)</li><li>Phase 2 efficacy trends referenced are not final (trial remains blinded/unblinded status pending)</li><li>Forward-looking plans subject to risks and uncertainties described in the company's filings</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/c1cd8b7e-f8ea-41f0-9476-059b91ba79d5" target="_blank">Original Article</a>
    </div>

    <div class="small">BRTX • TradersLink AI News</div>
  </div>
</body>
</html>